


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:49Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407549" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407549</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>ploscomp</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc-domain-id">328</journal-id><journal-id journal-id-type="pmc-domain">ploscomp</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407549</article-id><article-id pub-id-type="pmcid-ver">PMC12407549.1</article-id><article-id pub-id-type="pmcaid">12407549</article-id><article-id pub-id-type="pmcaiid">12407549</article-id><article-id pub-id-type="pmid">40828879</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399</article-id><article-id pub-id-type="publisher-id">PCOMPBIOL-D-25-00077</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Infectious Disease Immunology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Infectious Disease Immunology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Infectious Disease Immunology</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Europe</subject><subj-group><subject>European Union</subject><subj-group><subject>France</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Vaccine Development</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Vaccine Development</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Vaccine Development</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Leaky or polarised immunity: Non-Markovian modelling highlights the impact of immune memory assumptions</article-title><alt-title alt-title-type="running-head">Highlighting differences between leaky and polarised immunity using non-Markovian modeling</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4899-1240</contrib-id><name name-style="western"><surname>Reyn&#233;</surname><given-names initials="B">Bastien</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-rolesfFormal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamiya</surname><given-names initials="T">Tsukushi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Djidjou-Demasse</surname><given-names initials="R">Rams&#232;s</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Alizon</surname><given-names initials="S">Samuel</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sofonea</surname><given-names initials="MT">Mircea T.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Univ. Bordeaux, INSERM, INRIA, BPH, U1219, Bordeaux, France</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Vaccine Research Institute, Cr&#233;teil, France</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>MIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>CIRB, Coll&#232;ge de France, CNRS, INSERM, Universit&#233; PSL, Paris, France</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>&#201;cole Polytechnique de Thi&#232;s, Thi&#232;s, S&#233;n&#233;gal</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>PCCEI, Univ Montpellier, INSERM, Montpellier, France</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Anesthesiology, Critical Care, Intensive Care, Pain and Emergency Medicine, CHU N&#238;mes, N&#238;mes, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Kusejko</surname><given-names initials="K">Katharina</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>University Hospital Zurich, SWITZERLAND</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>bastien.reyne@inserm.fr</email> (BR); <email>mircea.sofonea@umontpellier.fr</email> (MTS)</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><volume>21</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494410</issue-id><elocation-id>e1013399</elocation-id><history><date date-type="received"><day>14</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Reyn&#233; et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Reyn&#233; et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="pcbi.1013399.pdf"/><self-uri content-type="pdf" xlink:href="pcbi.1013399.pdf"/><related-article related-article-type="editor-report" xml:lang="en" journal-id="PLoS Comput Biol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40828879"><article-title>Leaky or polarised immunity: Non-Markovian modelling highlights the impact of immune memory assumptions.</article-title><volume>21</volume><issue>8</issue><date><day>19</day><month>8</month><year>2025</year></date><fpage>e1013399</fpage><lpage>e1013399</lpage><source>PLoS Comput Biol</source><pub-id pub-id-type="doi">10.1371/journal.pcbi.1013399</pub-id><pub-id pub-id-type="pmid">40828879</pub-id></related-article><related-article related-article-type="reviewed-article" xml:lang="en" journal-id="PLoS Comput Biol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40828879"><article-title>Leaky or polarised immunity: Non-Markovian modelling highlights the impact of immune memory assumptions.</article-title><volume>21</volume><issue>8</issue><date><day>19</day><month>8</month><year>2025</year></date><fpage>e1013399</fpage><lpage>e1013399</lpage><source>PLoS Comput Biol</source><pub-id pub-id-type="doi">10.1371/journal.pcbi.1013399</pub-id><pub-id pub-id-type="pmid">40828879</pub-id></related-article><abstract><p>Mathematical models tend to oversimplify the biological details of vaccine or infection-derived immunity effectiveness. Yet, epidemiological outcomes may diverge when assuming polarised immunity&#8212;individuals are either fully susceptible or completely immune&#8212;compared to leaky immunity&#8212;where all individuals are partially protected. We explore the differences between the two by taking advantage of a non-Markovian framework, which allows us to explicitly record the &#8216;age&#8217; of the immunity and vary its effectiveness accordingly. A basic scenario reveals that leaky immunity leads to a shorter time between reinfections. A more data-driven scenario based on SARS-CoV-2 data finds that leaky immunity yields substantially more reinfections than polarised immunity and a higher number of infected individuals, yet with a lower probability of hospitalisation. Our findings emphasize the critical role of immune memory modelling assumptions, especially for long-term epidemiological dynamics and public health policies.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Epidemiological models that incorporate immunity often rely on strong assumptions about immune memory, yet the assumptions are rarely acknowledged or justified. Using a non-Markovian framework, we explore the implications of choosing leaky immunity (all hosts are partially protected) over more commonly assumed polarised one (some hosts are fully protected and the others fully susceptible), We find that leaky immunity comes with a shorter time between reinfections and alters estimations of some metrics such as the number of reinfections.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-21-EXES-0005</award-id><principal-award-recipient><name name-style="western"><surname>Djidjou-Demasse</surname><given-names>Rams&#232;s</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-21-EXES-0005</award-id><principal-award-recipient><name name-style="western"><surname>Sofonea</surname><given-names>Mircea T.</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>ANRS MIE</institution></funding-source><award-id>ANRS-24-PEPRMIE-0003 PReViX</award-id><principal-award-recipient><name name-style="western"><surname>Sofonea</surname><given-names>Mircea T.</given-names></name></principal-award-recipient></award-group><funding-statement>RDD and MTS acknowledge funding from the ExposUM Institute of the University of Montpellier (funded by the Agence Nationale de la Recherche, ANR-21-EXES-0005, part of the France 2030 programme, and by the Occitanie Region; NEXUS EMIPSA project). MTS also acknowledges funding from the ANRS Maladies Infectieuses &#201;mergentes and France 2030 (ANRS-24-PEPRMIE-0003 PReViX project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="15"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Code is available on Zenodo or GitLab <ext-link xlink:href="https://gitlab.com/reyb/immunity-leaky-vs-polarised" ext-link-type="uri">https://gitlab.com/reyb/immunity-leaky-vs-polarised</ext-link>; <ext-link xlink:href="https://doi.org/10.5281/zenodo.14620451" ext-link-type="uri">https://doi.org/10.5281/zenodo.14620451</ext-link>.</meta-value></custom-meta><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2025-09-03</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Code is available on Zenodo or GitLab <ext-link xlink:href="https://gitlab.com/reyb/immunity-leaky-vs-polarised" ext-link-type="uri">https://gitlab.com/reyb/immunity-leaky-vs-polarised</ext-link>; <ext-link xlink:href="https://doi.org/10.5281/zenodo.14620451" ext-link-type="uri">https://doi.org/10.5281/zenodo.14620451</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>1. Introduction</title><p>The early stages of the management of the COVID-19 pandemic faced uncertainties about the natural history of SARS-CoV-2 infection and subsequent immunity. Quite rapidly, estimates were published for the infection fatality ratio (IFR) [<xref rid="pcbi.1013399.ref001" ref-type="bibr">1</xref>], the generation time [<xref rid="pcbi.1013399.ref002" ref-type="bibr">2</xref>], and the basic reproduction number [<xref rid="pcbi.1013399.ref003" ref-type="bibr">3</xref>]. These key metrics helped to parameterise mathematical models, which were instrumental in informing short-term health policies. In particular, mathematical models were used to help determine the intensity of non-pharmaceutical interventions (NPIs) needed to contain the epidemic to avoid an overload of the healthcare system [<xref rid="pcbi.1013399.ref004" ref-type="bibr">4</xref>,<xref rid="pcbi.1013399.ref005" ref-type="bibr">5</xref>]. Less than a year later, while the first vaccines were being deployed, the arrival of the first variant of concern (VOC), Alpha, brought new uncertainties to epidemiological modelling given its increased transmissibility and virulence [<xref rid="pcbi.1013399.ref006" ref-type="bibr">6</xref>&#8211;<xref rid="pcbi.1013399.ref009" ref-type="bibr">9</xref>]. Later, long-term surveillance efforts demonstrated that the effectiveness of vaccination or infection-derived immunity tends to decline over time [<xref rid="pcbi.1013399.ref010" ref-type="bibr">10</xref>,<xref rid="pcbi.1013399.ref011" ref-type="bibr">11</xref>]. Notably, in late 2021, the emergence of Omicron VOCs with increased transmissibility, due to their strong immune escape properties, rendered the immunity component paramount in mathematical models [<xref rid="pcbi.1013399.ref008" ref-type="bibr">8</xref>]. By this time, however, models were already parametrised and ran in routine, and this new evidence regarding immunity was implemented on top of already existing models, leading many modellers to keep the initial assumptions regarding immunity. These initial assumptions often assumed perfect natural immunity, or imperfect immunity with a constant (over the age of immunity) increase in susceptibility relative to Omicron or an increased loss rate of immunity. This (lack of) justification for the assumptions regarding immunity in SARS-CoV-2 models was mostly due to the urgency of the context and the need for timely short-term projections. Indeed, these assumptions did not require changes in the core structure of the model as the differences would have been negligible over such short periods. However, these additional assumptions obscured competing views on the functioning of immunity, which few studies acknowledged (but see [<xref rid="pcbi.1013399.ref012" ref-type="bibr">12</xref>]).</p><p>There is a dense literature on modelling imperfect immunity, as this problem arises for many pathogens. Some of the earliest examples are variations of the well-known <italic toggle="yes">Susceptible &#8211; Infected&#8212;Recovered</italic> (<italic toggle="yes">SIR</italic>) model that relaxed the assumption of perfect immunity. For example, it is the case of the <italic toggle="yes">SIS</italic> model [<xref rid="pcbi.1013399.ref013" ref-type="bibr">13</xref>]&#8212;where individuals become susceptible again immediately after an infection&#8212;and the <italic toggle="yes">SIRS</italic> model [<xref rid="pcbi.1013399.ref014" ref-type="bibr">14</xref>], where perfect immunity waned over time. These early studies focused on mathematical properties and asymptotic behaviours of the dynamical systems and laid the foundation for later work specific to particular pathogens, such as gonorrhoea for the <italic toggle="yes">SIS</italic> model [<xref rid="pcbi.1013399.ref015" ref-type="bibr">15</xref>] or syphilis [<xref rid="pcbi.1013399.ref016" ref-type="bibr">16</xref>] and influenza [<xref rid="pcbi.1013399.ref017" ref-type="bibr">17</xref>] for the <italic toggle="yes">SIRS</italic> model.</p><p>Some statistical approaches were also developed to quantify the effectiveness of imperfect immunity [<xref rid="pcbi.1013399.ref018" ref-type="bibr">18</xref>]. Such an effort was particularly prolific in the context of vaccination where vaccine trials were specifically designed to estimate the vaccine effectiveness. In their review, [<xref rid="pcbi.1013399.ref019" ref-type="bibr">19</xref>] elaborated the different interpretations and conceptions behind what appears at first as a simple estimation of vaccine efficacy. Indeed, two competing viewpoints are brought to light. In the first one, the vaccine is assumed to be <italic toggle="yes">leaky</italic>, meaning that it protects everyone homogeneously but imperfectly to a certain degree. In the second, the vaccine is assumed to protect only a fraction of the individuals but with perfect protection. We refer to this all-or-nothing pattern as <italic toggle="yes">polarised</italic>, following a terminology introduced by [<xref rid="pcbi.1013399.ref020" ref-type="bibr">20</xref>]. For a level of immunity <inline-formula id="pcbi.1013399.e001"><alternatives><graphic id="pcbi.1013399.e001g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e001.jpg"/><mml:math id="M1" display="inline" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi><mml:mo>&#8712;</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> at a given time in the population that presents the same effectiveness, the leaky formulation assumes that each individual benefits from a decrease in susceptibility of <italic toggle="yes">x</italic>, whereas the polarised one assumes that <italic toggle="yes">x</italic> individuals are perfectly immune and 1&#8211;<italic toggle="yes">x</italic> are entirely susceptible (<xref rid="pcbi.1013399.g001" ref-type="fig">Fig 1A</xref>). Both of these formalisms are consistent with the definition of vaccine effectiveness [<xref rid="pcbi.1013399.ref021" ref-type="bibr">21</xref>], which is defined as the ratio of incidence rates between vaccinated (immunised) and unvaccinated (susceptible) individuals. Both are also valid implementations of the (ill-defined) term of <italic toggle="yes">imperfect immunity</italic> in mathematical language. Therefore, this lack of precision begs the question: &#8216;Does imperfect immunity equate 1) full protection only for some or 2) partial protection for all?&#8217; Note these two presented formalisms could be seen as particular cases of a more general pattern that could account both for individuals perfectly or partially immune and thus may overlook other particular cases such as immune boosting where exposure may reinforce immunity [<xref rid="pcbi.1013399.ref020" ref-type="bibr">20</xref>].</p><fig position="float" id="pcbi.1013399.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1013399.g001</object-id><label>Fig 1</label><caption><title>Illustration of the leaky and polarised formalisms and how they can be modelled.</title><p><bold>A.</bold> Differences between leaky and polarised formalisms. <bold>B.</bold> How this distinction interacts with immunity waning. <bold>C.</bold> Simplest non-Markovian formulation of the <italic toggle="yes">Susceptible &#8211; Infected &#8211; Recovered</italic> to incorporate imperfect immunisation for each formalism.</p></caption><graphic position="float" orientation="portrait" xlink:href="pcbi.1013399.g001.jpg"/></fig><p>One difficulty in choosing between these two points of view comes from the lack of a direct comparison between them. To determine whether immunity is leaky or polarised at a given time after recovery, we must track the duration spent in the recovered compartment and specify the corresponding immunity level. This requirement calls for a non-Markovian assumption of immune memory, in which the infectious and immunological history of an individual (<italic toggle="yes">e.g.</italic> how long they have been recovered for) affects the probability of occurrence of some events (<italic toggle="yes">e.g.</italic> the probability to be reinfected the next day).</p><p>In this study, we aim to highlight the main differences and the intricacies implied by assuming a leaky or a polarised immunity to model imperfect immunity (<xref rid="pcbi.1013399.g001" ref-type="fig">Fig 1B</xref>). Some of the vast data gathered during the SARS-CoV-2 support the hypothesis that the immunity to this specific pathogen is leaky. In particular, [<xref rid="pcbi.1013399.ref022" ref-type="bibr">22</xref>] reached this conclusion by using a closed-setting (correctional facilities) to assess the reinfection risk while estimating the overall temporal exposure. However, nothing guarantees this to be a general rule for every pathogen as controlled reinfection data remain rare. Building on an existing mathematical modelling framework to explicitly track the time since the recovery (<italic toggle="yes">i.e.</italic> the age of immunity) [<xref rid="pcbi.1013399.ref005" ref-type="bibr">5</xref>,<xref rid="pcbi.1013399.ref023" ref-type="bibr">23</xref>], we perform rigorous comparisons between the two viewpoints, with the flexibility to assume any specified function representing the decline of immunity over time. For the polarised assumption, the <italic toggle="yes">SIRS</italic> model is the simplest formulation under this assumption. For the leaky assumption, we postulate that a recovered individual can be reinfected directly without going back into the susceptible compartment <italic toggle="yes">S</italic> [<xref rid="pcbi.1013399.ref024" ref-type="bibr">24</xref>]. The path followed by an individual is then <inline-formula id="pcbi.1013399.e002"><alternatives><graphic id="pcbi.1013399.e002g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e002.jpg"/><mml:math id="M2" display="inline" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mo>&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mo>&#8594;</mml:mo><mml:mi>R</mml:mi><mml:mo>&#8594;</mml:mo><mml:mi>I</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>, so we refer to this model as <italic toggle="yes">SIRI</italic> (<xref rid="pcbi.1013399.g001" ref-type="fig">Fig 1C</xref>). We first highlight the differences between the two formalisms using simple models, before assessing the practical issues arising in a specific, data-driven setting by fitting the first SARS-CoV-2 Omicron epidemic waves, for which there are reliable estimations of the level of imperfect immunisation.</p></sec><sec sec-type="results" id="sec002"><title>2. Results</title><p>We first compare the time spent uninfected in the leaky and polarised formalisms in a simple discrete-time setting where we assume a constant force of infection and the same decreasing function <inline-formula id="pcbi.1013399.e003"><alternatives><graphic id="pcbi.1013399.e003g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e003.jpg"/><mml:math id="M3" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#183;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> that represents the immunity efficacy and depends on the age of immunity. We assume all individuals gained immunity at the same time (<inline-formula id="pcbi.1013399.e004"><alternatives><graphic id="pcbi.1013399.e004g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e004.jpg"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#964;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>), and we study the proportion that is reinfected over time. Under the leaky immunity assumption, <inline-formula id="pcbi.1013399.e005"><alternatives><graphic id="pcbi.1013399.e005g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e005.jpg"/><mml:math id="M5" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> represents the decrease in susceptibility <italic toggle="yes">&#964;</italic> days after acquiring immunity. The proportion of remaining uninfected individuals (<inline-formula id="pcbi.1013399.e006"><alternatives><graphic id="pcbi.1013399.e006g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e006.jpg"/><mml:math id="M6" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) at time <inline-formula id="pcbi.1013399.e007"><alternatives><graphic id="pcbi.1013399.e007g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e007.jpg"/><mml:math id="M7" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> is</p><disp-formula id="pcbi.1013399.e008"><alternatives><graphic id="pcbi.1013399.e008g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e008.jpg"/><mml:math id="M8" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8722;</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mi>&#923;</mml:mi></mml:mrow><mml:mo>&#9183;</mml:mo></mml:munder><mml:mrow><mml:mtext>newly&#160;infected&#160;individuals</mml:mtext></mml:mrow></mml:munder><mml:mo>=</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>&#923;</mml:mi><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>&#923;</mml:mi><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula><p>where &#923; represents the force of infection.</p><p>Under the polarised immunity assumption, <inline-formula id="pcbi.1013399.e009"><alternatives><graphic id="pcbi.1013399.e009g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e009.jpg"/><mml:math id="M9" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> represents the proportion completely immune at time <italic toggle="yes">&#964;</italic>. We may decompose the proportion of remaining uninfected individuals (<italic toggle="yes">q</italic><sub><italic toggle="yes">p</italic></sub>) at time <italic toggle="yes">&#964;</italic> as <inline-formula id="pcbi.1013399.e010"><alternatives><graphic id="pcbi.1013399.e010g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e010.jpg"/><mml:math id="M10" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1013399.e011"><alternatives><graphic id="pcbi.1013399.e011g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e011.jpg"/><mml:math id="M11" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> (resp. <inline-formula id="pcbi.1013399.e012"><alternatives><graphic id="pcbi.1013399.e012g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e012.jpg"/><mml:math id="M12" display="inline" overflow="scroll"><mml:mrow><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>) represent the completely immune (resp. susceptible) individuals at time <italic toggle="yes">&#964;</italic>. The proportion of uninfected individuals at time <inline-formula id="pcbi.1013399.e013"><alternatives><graphic id="pcbi.1013399.e013g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e013.jpg"/><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> is given by</p><disp-formula id="pcbi.1013399.e014"><alternatives><graphic id="pcbi.1013399.e014g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e014.jpg"/><mml:math id="M14" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mspace linebreak="newline"/><mml:mo>=</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:munder><mml:mrow><mml:munder><mml:mrow><mml:munder><mml:mrow><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>&#923;</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>&#9183;</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mtext>susceptible&#160;not&#160;infected</mml:mtext></mml:mrow></mml:munder></mml:mrow><mml:mrow><mml:mtext>among&#160;already&#160;susceptible</mml:mtext></mml:mrow></mml:munder><mml:mo>+</mml:mo><mml:munder><mml:mrow><mml:munder><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>&#9183;</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mtext>new&#160;susceptible</mml:mtext></mml:mrow></mml:munder><mml:mo>,</mml:mo><mml:mspace linebreak="newline"/><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>&#923;</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mspace linebreak="newline"/><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>&#923;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo><mml:mspace linebreak="newline"/><mml:mo>=</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>&#923;</mml:mi><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>&#923;</mml:mi><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula><p>We assume <inline-formula id="pcbi.1013399.e015"><alternatives><graphic id="pcbi.1013399.e015g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e015.jpg"/><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. As detailed in Sect A.1 in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>, it can be shown that <inline-formula id="pcbi.1013399.e016"><alternatives><graphic id="pcbi.1013399.e016g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e016.jpg"/><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1013399.e017"><alternatives><graphic id="pcbi.1013399.e017g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e017.jpg"/><mml:math id="M17" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8804;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>. By induction, we may extend this inequality beyond time <italic toggle="yes">t</italic>&#8201;=&#8201;2, to any time by assuming it to be true at time <inline-formula id="pcbi.1013399.e018"><alternatives><graphic id="pcbi.1013399.e018g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e018.jpg"/><mml:math id="M18" display="inline" overflow="scroll"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>&#964;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>, (meaning <inline-formula id="pcbi.1013399.e019"><alternatives><graphic id="pcbi.1013399.e019g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e019.jpg"/><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>&#8467;</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8804;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>), this inequality remains true at time <inline-formula id="pcbi.1013399.e020"><alternatives><graphic id="pcbi.1013399.e020g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e020.jpg"/><mml:math id="M20" display="inline" overflow="scroll"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>&#964;</mml:mi><mml:mspace width="0.167em"/><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mspace width="0.167em"/><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> thanks to <xref rid="pcbi.1013399.e008" ref-type="disp-formula">Eqs (1)</xref>&#8211;(<xref rid="pcbi.1013399.e014" ref-type="disp-formula">2</xref>). This proves individuals are reinfected more quickly through leaky than polarised immunity&#8212;assuming the function <inline-formula id="pcbi.1013399.e021"><alternatives><graphic id="pcbi.1013399.e021g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e021.jpg"/><mml:math id="M21" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#183;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> is decreasing. This can be further demonstrated numerically with a variety of decreasing functions <inline-formula id="pcbi.1013399.e022"><alternatives><graphic id="pcbi.1013399.e022g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e022.jpg"/><mml:math id="M22" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#183;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, as shown in <xref rid="pcbi.1013399.g002" ref-type="fig">Fig 2</xref>.</p><fig position="float" id="pcbi.1013399.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1013399.g002</object-id><label>Fig 2</label><caption><title>Time spent uninfected with the leaky and polarised formalisms (on the right) given the imperfect immunity function (on the left).</title><p>The force of infection is assumed to be constant (<inline-formula id="pcbi.1013399.e023"><alternatives><graphic id="pcbi.1013399.e023g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e023.jpg"/><mml:math id="M23" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#923;</mml:mi><mml:mo>=</mml:mo><mml:mn>0.005</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>) and all the other parameters are default. More details in Sect A in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="pcbi.1013399.g002.jpg"/></fig><p>This comparison highlights the divergent outcomes when assuming leaky versus polarised immunity, however, the application remains restricted to cases where the force of infection is known. To explore the implications over time with multiple reinfections in a dynamical setting, when the differences between formalisms accumulate over time, we implement a more realistic scenario capturing the dynamics of the first Omicron epidemic waves on hospital admissions in France. In particular, we focus on the impact of the choice of immunity on the inference of key epidemic parameters, such as the probability of being hospitalised following an infection. The transmission models for each paradigm are illustrated in <xref rid="pcbi.1013399.g003" ref-type="fig">Fig 3</xref>. The main difference is that recovered compartments are followed by a susceptible one in the polarised formalism whereas recovered individuals in the leaky paradigm are reinfected directly. Additional details can be found in the Methods and models section.</p><fig position="float" id="pcbi.1013399.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1013399.g003</object-id><label>Fig 3</label><caption><title>Structure of the Omicron epidemic waves models.</title><p>The model assumes imperfect immunity that acts as an age-dependent decrease in susceptibility in the leaky model and an age-dependent departure rate from the recovered compartment in the polarised one. Before the emergence of the first Omicron VOC, we assume everyone has been immunised for SARS-CoV-2 (past infection or vaccination).</p></caption><graphic position="float" orientation="portrait" xlink:href="pcbi.1013399.g003.jpg"/></fig><p>The model assuming either form of immune memory could effectively capture the hospital admissions dynamic (<xref rid="pcbi.1013399.g004" ref-type="fig">Fig 4A</xref>). However, differences are observed in key epidemiological outcomes. Since the leaky formalism induces shorter times before reinfections than the polarised one, it exhibits a greater cumulated number of reinfections over time (<xref rid="pcbi.1013399.g004" ref-type="fig">Fig 4B</xref>). From the emergence of Omicron in France (November 26<sup>th</sup>, 2021) to the end of the monitoring (January 31<sup>st</sup>, 2023), this corresponds to a difference of 4 million reinfections (and a wider uncertainty). The prevalence is also higher in the leaky model than in the polarised one at all times (<xref rid="pcbi.1013399.g004" ref-type="fig">Fig 4C</xref>). Finally, there are also differences in terms of the force of infection (Fig A in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>) and hospitalisation probability (<xref rid="pcbi.1013399.g004" ref-type="fig">Fig 4D</xref>).</p><fig position="float" id="pcbi.1013399.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pcbi.1013399.g004</object-id><label>Fig 4</label><caption><title>Comparison of the leaky and polarised formalisms applied to Omicron epidemic waves.</title><p><bold>A.</bold> Fit of the Omicron epidemic waves with both models. Black crosses represent daily hospital admissions in France. <bold>B.</bold> 95% posterior trajectories interval of the estimated cumulative number of reinfections and of the <bold>C.</bold> number of infected individuals per day. <bold>D.</bold> Posterior probability of hospitalisation following an infection.</p></caption><graphic position="float" orientation="portrait" xlink:href="pcbi.1013399.g004.jpg"/></fig><p>These results hold for different transmission rates, timespans as well as different initialisations for the <inline-formula id="pcbi.1013399.e026"><alternatives><graphic id="pcbi.1013399.e026g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e026.jpg"/><mml:math id="M26" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mi>D</mml:mi></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> compartment, as shown by sensitivity analyses (Sect G in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>).</p></sec><sec sec-type="conclusions" id="sec003"><title>3. Discussion</title><p>Immunity is rarely perfect in that some people contract infections when others do not under the same circumstances of exposure to infection. However, this phenomenon can correspond to different immunological realities: <italic toggle="yes">i.e.</italic>, all individuals can be partially protected (the &#8216;leaky&#8217; paradigm), or some of the individuals may be fully immune while others are fully susceptible (the &#8216;polarised&#8217; paradigm) among the most popular formalisms. This study aimed to highlight the methodological and dynamical differences of modelling imperfect immunity, and demonstrate implications for epidemiological outcomes. From a mathematical standpoint, we showed that a leaky immunity generates a shorter average time between reinfections in the population than a polarised one.</p><p>Using a data-driven scenario of the epidemic of the Omicron variant of the SARS-CoV-2 on a medium-term scale, we can corroborate a greater number of reinfections over time when assuming leaky immunity (<xref rid="pcbi.1013399.g004" ref-type="fig">Fig 4B</xref>). Since we focused on a limited period, the absolute number of SARS-CoV-2 reinfections is likely to be underestimated. We may also notice an overall higher number of infected individuals with leaky immunity perhaps because shorter immunity induces more individuals to be reinfected sooner. This in turn could further increase the force of infection and thus sustain a higher level of infected individuals. However, since this is balanced out by a lower probability of hospitalisation, we observe a similar number of hospitalisations in both formalisms. Because the force of infection (through the transmission rates) is fitted to reproduce observed hospitalisation data in both cases, it is tempting to conclude that the differences are negligible from a practical point of view and have little impact on the produced results in some cases. However, such an assertion neglects the key role of the number of re/infections, and its documented impact on long-COVID, next epidemic waves projections, or the probability of the emergence of new strains. Note also, that we made some simplifying assumptions that might have been questioned in a real-life applied case. In particular, we assumed homogeneity in the population both in terms of susceptibility and contact where there is a difference, in reality, [<xref rid="pcbi.1013399.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1013399.ref023" ref-type="bibr">23</xref>]. Although overall trends related to immunity and attack rates were similar across age groups in countries like France [<xref rid="pcbi.1013399.ref025" ref-type="bibr">25</xref>], further studies explicitly accounting for the age structure of the population are needed to effectively assess its impact in the setting developed here. We also neglect death in our model, which is not linked to the choice of the immunity formalism, although it could have marginally diminished the number of reinfections. We neglected the Omicron sub-lineages that could carry different phenotypic traits (and possibly some immune evasion properties) that have been absorbed in the transmission rates. Finally, we pooled all immunological profiles on a unique recovered compartments that account for all types of immunity (infection derived immunity, different vaccination profiles), and only took into account the age of immunity as factor influencing the efficacy. Beyond that, other assumptions such as the initialisation of the initial level of immunity or the choice of the timespan for the transmission rates have little impact on the results (<italic toggle="yes">cf.</italic> Sect G in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>).</p><p>Nevertheless, the differences we identify remain negligible in the short term (at least in the case of SARS-CoV-2, where hospital admissions could be well predicted up to five weeks [<xref rid="pcbi.1013399.ref026" ref-type="bibr">26</xref>]) since immunity intervenes on longer time scales (here, a year without NPIs). This implies the difference arising in the choice of the immunity paradigm can go unnoticed in the short term&#8212;even if we may observe some differences in the projections made, see Sect H in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>. Worst, it could remain undetected in cases where the transmission rate is fitted periodically to provide short-term projections (as in [<xref rid="pcbi.1013399.ref026" ref-type="bibr">26</xref>] for the SARS-CoV-2 pandemic). The long-term effects on reinfections are difficult to anticipate, but a plausible consequence would be an underestimation of the number of recovered individuals if the &#8220;true immunity" lies closer to the leaky formalism than the polarised one, as [<xref rid="pcbi.1013399.ref022" ref-type="bibr">22</xref>] suggests. Both assumptions were made in the SARS-CoV-2 literature. For example, [<xref rid="pcbi.1013399.ref012" ref-type="bibr">12</xref>] used the leaky paradigm, [<xref rid="pcbi.1013399.ref027" ref-type="bibr">27</xref>] used the polarised formalism, and [<xref rid="pcbi.1013399.ref028" ref-type="bibr">28</xref>] tried both approaches. We may also wonder about the underlying motivations for some studies that assumed a polarised immunity for circulating strains, but a leaky one for new strains evading previously built immunity [<xref rid="pcbi.1013399.ref029" ref-type="bibr">29</xref>,<xref rid="pcbi.1013399.ref030" ref-type="bibr">30</xref>]. Eventually, [<xref rid="pcbi.1013399.ref022" ref-type="bibr">22</xref>] provided real-life observational evidence in favour of leaky immunity.</p><p>Our results follow a long list of previous modelling studies that tried to capture imperfect immunity using compartmental models [<xref rid="pcbi.1013399.ref031" ref-type="bibr">31</xref>&#8211;<xref rid="pcbi.1013399.ref034" ref-type="bibr">34</xref>]. However, the insights from these earlier works remained theoretical because they used only one compartment to model (partly) immune individuals (vaccinated or recovered). Our results also complement other historical works that investigated how to estimate vaccine effectiveness from clinical studies early on [<xref rid="pcbi.1013399.ref018" ref-type="bibr">18</xref>,<xref rid="pcbi.1013399.ref019" ref-type="bibr">19</xref>,<xref rid="pcbi.1013399.ref021" ref-type="bibr">21</xref>] that led the way to assess the level of immunity waning. Most of the estimations of immune waning are made using antibody titres, as in the case of SARS-CoV-2 [<xref rid="pcbi.1013399.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1013399.ref036" ref-type="bibr">36</xref>], or with a focus on the link between antibody titres and the time between reinfections in the case of other coronaviruses such as 229E and OC43 [<xref rid="pcbi.1013399.ref037" ref-type="bibr">37</xref>,<xref rid="pcbi.1013399.ref038" ref-type="bibr">38</xref>]. However, antibodies are one component among many involved in the functioning of immunity, and the link between antibodies and the level of protection is not straightforward. Still, assuming that they can serve as correlates of protection, they can highlight the impact of the individual-level variability in the immune response, with sometimes a high level of dispersion in the immunity efficacy estimations [<xref rid="pcbi.1013399.ref039" ref-type="bibr">39</xref>]. In our study, we made a simplifying assumption that disregards any forms of heterogeneity other than the time-acquisition declining immunity. This helps have a clearest overall behaviour and pattern, but it is not well-suited to modelling reinfections of weakly protected individuals.</p><p>On the methodological level, non-Markovian models are convenient to account for medium-term immunity waning as they allow us to explicitly parameterise the level of protection, whether assuming leaky or polarised immunity. In this study, we explored both assumptions using a discrete-time approach (following [<xref rid="pcbi.1013399.ref005" ref-type="bibr">5</xref>]): advantages of this approach and alternatives(<italic toggle="yes">e.g.,</italic> partial differential equations [<xref rid="pcbi.1013399.ref023" ref-type="bibr">23</xref>,<xref rid="pcbi.1013399.ref040" ref-type="bibr">40</xref>]) are detailed in Sect B.3 in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>. There are also other attempts in the literature. For instance, in the line of the theoretical study by [<xref rid="pcbi.1013399.ref041" ref-type="bibr">41</xref>], some studies use the &#8216;chain trick&#8217; on recovered compartments to add some heterogeneity in the imperfect immunity without departing from the classical ODE framework [<xref rid="pcbi.1013399.ref042" ref-type="bibr">42</xref>&#8211;<xref rid="pcbi.1013399.ref044" ref-type="bibr">44</xref>]. There are also less conventional ODEs-based models, such as the ones based on hyper-exponential waiting distributions [<xref rid="pcbi.1013399.ref045" ref-type="bibr">45</xref>], where individuals may enter different compartments (with some probability), each compartment having its waiting time distribution. This results in an overall distribution with a standard deviation higher than its expectation (hence the name hyper-exponential). This may present an interesting alternative to hypo-exponential distributions when dealing with highly variable biological distributions.</p><p>Part of the challenge in modelling imperfect immunity stems from the numerous unknowns surrounding the underlying mechanisms. One possibility to cope with this uncertainty is to adopt a flexible framework that allows for continuity between leaky and polarised immunity [<xref rid="pcbi.1013399.ref020" ref-type="bibr">20</xref>,<xref rid="pcbi.1013399.ref046" ref-type="bibr">46</xref>] (and see Sect I <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>, for a simple hybrid model). Other possibilities may include allowing a fraction of individuals to recover and the other fraction to go back straight into the susceptible compartments (<italic toggle="yes">e.g.</italic> immunocompromised individuals). [<xref rid="pcbi.1013399.ref020" ref-type="bibr">20</xref>] also consider the possibility of immune-boosting mechanisms where exposure could reinforce individual immunity even if infection fails to establish. The level of data granularity we would need to provide population estimates is beyond immediate reach, as it would imply a controlled setting and be able to control exposure on individuals which is ethically questionable. Nonetheless, accounting for this hypothesis may already provide some new information, as in the case of [<xref rid="pcbi.1013399.ref047" ref-type="bibr">47</xref>] where they provide counterfactuals on the pertussis prevalence according to various levels of immunity boosting. Complementary to the immune boosting theory, [<xref rid="pcbi.1013399.ref048" ref-type="bibr">48</xref>] modelled the immune response given different inoculum sizes and observed non-linear and non-monotonic infection duration, which may open perspectives to linking the level of exposure with a given outcome &#8212; infection or boosted immunity.</p><p>In the meantime, statistical estimations of the type of immunity through closed settings [<xref rid="pcbi.1013399.ref022" ref-type="bibr">22</xref>] and temporal meta-analytic estimations of the immunity effectiveness [<xref rid="pcbi.1013399.ref011" ref-type="bibr">11</xref>], may provide a good starting point in modelling epidemics at a medium-term scale. We acknowledge that our study falls short of providing any heuristic for selecting among various possibilities for all communicable diseases. However, our hope is to highlight the key role of partial immunity assumptions, which remain seldom addressed.</p></sec><sec id="sec004"><title>4. Models and method</title><p>To address the question of the length of immunity in a real-world setting with a variable force of infection, we use non-Markovian discrete-time models. The overall idea behind non-Markovian models is to include residence times that depart from the exponential (and memoryless) waiting time assumption classically involved with constant rate processes in ODE-based models. Here we choose an approach that allows us to track individuals over time explicitly [<xref rid="pcbi.1013399.ref005" ref-type="bibr">5</xref>]. Using this approach, we may specify that individuals that recovered <italic toggle="yes">a</italic> days age at time <italic toggle="yes">t</italic>, <italic toggle="yes">R</italic><sub><italic toggle="yes">t</italic>,<italic toggle="yes">a</italic></sub> are subject to age-dependent processes, thereby allowing for reduced the force of infection in the leaky immunity assumption (<italic toggle="yes">i.e.</italic> a multiplying factor of <inline-formula id="pcbi.1013399.e027"><alternatives><graphic id="pcbi.1013399.e027g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e027.jpg"/><mml:math id="M27" display="inline" overflow="scroll"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>&#958;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> on the force of infection) or an age-dependent rate to return to the susceptible compartment, <inline-formula id="pcbi.1013399.e028"><alternatives><graphic id="pcbi.1013399.e028g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e028.jpg"/><mml:math id="M28" display="inline" overflow="scroll"><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>&#963;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, in the polarised immunity. Additional details on the origin of non-Markovian models, the main different competing implementations that exist, and how to choose between them are available in Sect B in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>.</p><sec id="sec005"><title>Modelling the initial waves of the Omicron variant</title><p>We implement two models focusing on SARS-CoV-2 hospital admissions data, one with leaky immunity and another one with polarised immunity. Our analysis focused on comparing the differences in the resulting epidemic dynamics on a long-term scale. Our focus is specifically on the Omicron period in France, beginning with its estimated introduction on November <inline-formula id="pcbi.1013399.e029"><alternatives><graphic id="pcbi.1013399.e029g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e029.jpg"/><mml:math id="M29" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mn>26</mml:mn><mml:mrow><mml:mtext>th</mml:mtext></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>, 2021 [<xref rid="pcbi.1013399.ref049" ref-type="bibr">49</xref>], and extending through to the end of official monitoring on January <inline-formula id="pcbi.1013399.e030"><alternatives><graphic id="pcbi.1013399.e030g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e030.jpg"/><mml:math id="M30" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mn>31</mml:mn><mml:mrow><mml:mtext>st</mml:mtext></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>, 2023. To simplify the initial situation, we assume a single age group and that everyone has already been immunised (either through infection-derived immunity or vaccination) by the time the Omicron BA.1 variant arrived. Although full immunisation was not achieved in practice, our aim is not to replicate the exact course of the French epidemic. Instead, we seek to highlight the significance of how immunity is defined within a plausible scenario. Depending on the immunity assumption, recovered individuals from Delta or previous strains or previously vaccinated (<inline-formula id="pcbi.1013399.e031"><alternatives><graphic id="pcbi.1013399.e031g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e031.jpg"/><mml:math id="M31" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> compartment) may be infected directly by the Omicron strain (in the model with leaky immunity) or become susceptible (<inline-formula id="pcbi.1013399.e032"><alternatives><graphic id="pcbi.1013399.e032g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e032.jpg"/><mml:math id="M32" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>) before an Omicron infection (in the polarised approach). The <inline-formula id="pcbi.1013399.e033"><alternatives><graphic id="pcbi.1013399.e033g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e033.jpg"/><mml:math id="M33" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> compartment is initialised with a uniform distribution on [0, 700] &#8211; individuals remaining until day 700 in <inline-formula id="pcbi.1013399.e034"><alternatives><graphic id="pcbi.1013399.e034g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e034.jpg"/><mml:math id="M34" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> are considered entirely susceptible in both models. Being fully susceptible in both formalisms is either due to a decrease of susceptibility of 1 in the leaky model or going in the <inline-formula id="pcbi.1013399.e035"><alternatives><graphic id="pcbi.1013399.e035g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e035.jpg"/><mml:math id="M35" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mtext mathvariant="italic">S</mml:mtext><mml:mrow><mml:mtext mathvariant="italic">d</mml:mtext></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> compartment in the polarised one (see Sect G in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>).</p><p>Infected individuals are assumed to be divided into two groups, mild infections (<italic toggle="yes">I</italic>) and severe infections that always lead to hospitalisation (<italic toggle="yes">J</italic>), following a probability of hospitalisation (<italic toggle="yes">p</italic><sub><italic toggle="yes">h</italic></sub>) that we estimate from the data. Mildly infected individuals are assumed to recover directly and end up in the recovered compartment (<inline-formula id="pcbi.1013399.e036"><alternatives><graphic id="pcbi.1013399.e036g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e036.jpg"/><mml:math id="M36" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>). Severely infected individuals are hospitalised (<italic toggle="yes">H</italic>) before recovering while death was not modelled for simplicity. The delay distributions between mild infection and recovery, severe infection and hospital admission, and between hospital admission and recovery are parameterised using values from the literature ([<xref rid="pcbi.1013399.ref004" ref-type="bibr">4</xref>], as detailed in Sect E in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>). Once in the recovered compartments, individuals can be reinfected directly in the leaky case, with a decrease in susceptibility that depends on the time spent in the recovered state. In the polarised model, recovered individuals become susceptible (<inline-formula id="pcbi.1013399.e037"><alternatives><graphic id="pcbi.1013399.e037g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e037.jpg"/><mml:math id="M37" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula>) before getting reinfected. Both models are summarised in Fig <xref rid="pcbi.1013399.g003" ref-type="fig">3</xref>.</p><p>In our model, Omicron evades acquired immunity (infection-derived or vaccination) with a given and fixed function based on empirical data from [<xref rid="pcbi.1013399.ref011" ref-type="bibr">11</xref>], as detailed in Sect E in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>. Still building on the data from [<xref rid="pcbi.1013399.ref011" ref-type="bibr">11</xref>], we assume that the Omicron BA.1 strain induces an imperfect immunity that allows reinfection by the Omicron BA.1 strain (<italic toggle="yes">cf.</italic> Fig C in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>). Finally, we do not consider the following Omicron sub-variants.</p><p>Our time series of interest is the daily hospital admissions, which is publicly available from the French public health agency (Sant&#233; Publique France). We use a Bayesian approach similar to that described by [<xref rid="pcbi.1013399.ref050" ref-type="bibr">50</xref>] to fit the piece-wise transmission rates, the initial proportion of Omicron-infected individuals, and the probability of hospitalisation that match the Omicron-induced daily new hospitalisations. The number of newly hospitalised individuals on day <italic toggle="yes">t</italic> in the polarised model is given by</p><disp-formula id="pcbi.1013399.e038"><alternatives><graphic id="pcbi.1013399.e038g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e038.jpg"/><mml:math id="M38" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mtext>polarised</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>t</mml:mi></mml:munderover><mml:msub><mml:mi>&#950;</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>&#923;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula><p>where <italic toggle="yes">p</italic> is the probability of being hospitalised, <inline-formula id="pcbi.1013399.e039"><alternatives><graphic id="pcbi.1013399.e039g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e039.jpg"/><mml:math id="M39" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#923;</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> is (an approximation of) the force of infection on the day <italic toggle="yes">t</italic>, <inline-formula id="pcbi.1013399.e040"><alternatives><graphic id="pcbi.1013399.e040g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e040.jpg"/><mml:math id="M40" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#950;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>&#183;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> the delay distribution between infection and hospitalisation and <inline-formula id="pcbi.1013399.e041"><alternatives><graphic id="pcbi.1013399.e041g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e041.jpg"/><mml:math id="M41" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mtext>x</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> the individuals for which the strain <italic toggle="yes">x</italic> infection-acquired immunity waned. In the leaky model, we have</p><disp-formula id="pcbi.1013399.e042"><alternatives><graphic id="pcbi.1013399.e042g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e042.jpg"/><mml:math id="M42" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mtext>leaky</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>t</mml:mi></mml:munderover><mml:msub><mml:mi>&#950;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>&#923;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">[</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mi>&#958;</mml:mi><mml:mi>i</mml:mi><mml:mi>D</mml:mi></mml:msubsup><mml:mo fence="true" form="postfix" stretchy="true">]</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">[</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mi>&#958;</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo fence="true" form="postfix" stretchy="true">]</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula><p>where <inline-formula id="pcbi.1013399.e043"><alternatives><graphic id="pcbi.1013399.e043g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e043.jpg"/><mml:math id="M43" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>&#958;</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is the decrease in susceptibility that benefits individuals previously infected by strain <italic toggle="yes">x</italic> when exposed to Omicron <italic toggle="yes">i</italic> days after immunity acquisition, <inline-formula id="pcbi.1013399.e044"><alternatives><graphic id="pcbi.1013399.e044g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e044.jpg"/><mml:math id="M44" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mi>x</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is the number of recovered individuals from strain <italic toggle="yes">x</italic> on day <italic toggle="yes">j</italic>, <italic toggle="yes">i</italic> days after their immunity acquisition. Let <italic toggle="yes">N</italic> be the support of the recovered compartments. Note in both models, following the method developed in [<xref rid="pcbi.1013399.ref005" ref-type="bibr">5</xref>], we approximate the force of infection with</p><disp-formula id="pcbi.1013399.e045"><alternatives><graphic id="pcbi.1013399.e045g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e045.jpg"/><mml:math id="M45" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#923;</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo fence="true" form="prefix" stretchy="true">(</mml:mo><mml:mi>&#8475;</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mi>J</mml:mi><mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo fence="true" form="postfix" stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula><p>where <inline-formula id="pcbi.1013399.e046"><alternatives><graphic id="pcbi.1013399.e046g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e046.jpg"/><mml:math id="M46" display="inline" overflow="scroll"><mml:mrow><mml:mi>&#8475;</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> can be interpreted as the Omicron-era baseline reproduction number, <italic toggle="yes">c</italic><sub><italic toggle="yes">t</italic></sub> is the transmission rate on day <italic toggle="yes">t</italic>, <inline-formula id="pcbi.1013399.e047"><alternatives><graphic id="pcbi.1013399.e047g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e047.jpg"/><mml:math id="M47" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> the generation time distribution and <inline-formula id="pcbi.1013399.e048"><alternatives><graphic id="pcbi.1013399.e048g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e048.jpg"/><mml:math id="M48" display="inline" overflow="scroll"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:mspace width="0.167em"/><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mspace width="0.167em"/><mml:mi>J</mml:mi><mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> the number of infected individuals since <italic toggle="yes">i</italic> days on day <italic toggle="yes">t</italic>. If the leaky and polarised immunity assumptions share the same formula, the force of infection is different in each model as the transmission rate <italic toggle="yes">c</italic><sub><italic toggle="yes">t</italic></sub> is fitted for each model. Particularly, we use a Bayesian framework to estimate the transmission rate every 20 days (see Sect F in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>). All model equations are available in Sect D in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref> and details on the fitting procedure are provided in Sect F in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>.</p></sec><sec id="sec006"><title>Sensitivity analysis</title><p>We perform a sensitivity analysis on the initialisation of the <inline-formula id="pcbi.1013399.e049"><alternatives><graphic id="pcbi.1013399.e049g" position="anchor" orientation="portrait" xlink:href="pcbi.1013399.e049.jpg"/><mml:math id="M49" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> support to check the robustness of the result regardless of how we initialise the compartment. We test three other initialisations with different modes on the recovered support that ensure different levels of initial immunity given the immunity efficacy waning function.</p><p>We also perform a sensitivity analysis on the 20-day timespan window for the transmission rates to ensure it is not an artificial by-product to reproduce the observed dynamic. We also performed an out-of-sample validation on Google Mobility Data time series.</p><p>The results are available in Sect G in <xref rid="pcbi.1013399.s001" ref-type="supplementary-material">S1 Text</xref>.</p></sec></sec><sec id="sec007" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pcbi.1013399.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Text</label><caption><title>Supplementary information.</title><p>(PDF)</p></caption><media xlink:href="pcbi.1013399.s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>We thank the ETE modelling team and Olivier Supplisson for useful discussions.</p></ack><ref-list><title>References</title><ref id="pcbi.1013399.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Verity</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Okell</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Dorigatti</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Winskill</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Whittaker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Imai</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Estimates of the severity of coronavirus disease 2019 : a model-based analysis</article-title>. <source>Lancet Infect Dis.</source><year>2020</year>;<volume>20</volume>(<issue>6</issue>):<fpage>669</fpage>&#8211;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30243-7</pub-id><pub-id pub-id-type="pmid">32240634</pub-id><pub-id pub-id-type="pmcid">PMC7158570</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nishiura</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Linton</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Akhmetzhanov</surname><given-names>AR</given-names></name>. <article-title>Serial interval of novel coronavirus (COVID-19) infections</article-title>. <source>Int J Infect Dis.</source><year>2020</year>;<volume>93</volume>:<fpage>284</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijid.2020.02.060</pub-id><pub-id pub-id-type="pmid">32145466</pub-id><pub-id pub-id-type="pmcid">PMC7128842</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title>. <source>N Engl J Med.</source><year>2020</year>;<volume>382</volume>(<issue>13</issue>):<fpage>1199</fpage>&#8211;<lpage>207</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmid">31995857</pub-id><pub-id pub-id-type="pmcid">PMC7121484</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Salje</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kiem</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Lefrancq</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Courtejoie</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bosetti</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Paireau</surname><given-names>J</given-names></name>. <article-title>Estimating the burden of SARS-CoV-2 in France</article-title>. <source>Science.</source><year>2020</year>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">32404476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc3517</pub-id><pub-id pub-id-type="pmcid">PMC7223792</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Reyn&#233;</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Elie</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Djidjou-Demasse</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Selinger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Michalakis</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Memory is key in capturing COVID-19 epidemiological dynamics</article-title>. <source>Epidemics.</source><year>2021</year>;<volume>35</volume>:<fpage>100459</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.epidem.2021.100459</pub-id><pub-id pub-id-type="pmid">34015676</pub-id><pub-id pub-id-type="pmcid">PMC8076764</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Davies</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Abbott</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barnard</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Jarvis</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Kucharski</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Munday</surname><given-names>JD</given-names></name>, <etal>et al</etal>. <article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title>. <source>Science.</source><year>2021</year>;<volume>372</volume>(<issue>6538</issue>):eabg3055. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmid">33658326</pub-id><pub-id pub-id-type="pmcid">PMC8128288</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Volz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chand</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Geidelberg</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England</article-title>. <source>Nature.</source><year>2021</year>;<volume>593</volume>(<issue>7858</issue>):<fpage>266</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-021-03470-x</pub-id><pub-id pub-id-type="pmid">33767447</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Markov</surname><given-names>PV</given-names></name>, <name name-style="western"><surname>Ghafari</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lythgoe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Simmonds</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Stilianakis</surname><given-names>NI</given-names></name>, <etal>et al</etal>. <article-title>The evolution of SARS-CoV-2</article-title>. <source>Nat Rev Microbiol.</source><year>2023</year>;<volume>21</volume>(<issue>6</issue>):<fpage>361</fpage>&#8211;<lpage>79</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41579-023-00878-2</pub-id><pub-id pub-id-type="pmid">37020110</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Alizon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Haim-Boukobza</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Foulongne</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Verdurme</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Trombert-Paolantoni</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lecorche</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021</article-title> . <source>Euro Surveill.</source><year>2021</year>;<volume>26</volume>(<issue>28</issue>):<fpage>2100573</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.28.2100573</pub-id><pub-id pub-id-type="pmid">34269174</pub-id><pub-id pub-id-type="pmcid">PMC8284044</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Powell</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Kirsebom</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Stowe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ramsay</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Lopez-Bernal</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study</article-title>. <source>Lancet Infect Dis.</source><year>2023</year>;<volume>23</volume>(<issue>4</issue>):<fpage>435</fpage>&#8211;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00729-0</pub-id><pub-id pub-id-type="pmid">36436536</pub-id><pub-id pub-id-type="pmcid">PMC10032664</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref011"><label>11</label><mixed-citation publication-type="journal">COVID-19 Forecasting Team. <article-title>Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis</article-title>. <source>Lancet.</source><year>2023</year>;<volume>401</volume>(<issue>10379</issue>):<fpage>833</fpage>&#8211;<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(22)02465-5</pub-id><pub-id pub-id-type="pmid">36930674</pub-id><pub-id pub-id-type="pmcid">PMC9998097</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bosetti</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tran Kiem</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Andronico</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Colizza</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Yazdanpanah</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fontanet</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France</article-title>. <source>BMC Med.</source><year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>33</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12916-022-02235-1</pub-id><pub-id pub-id-type="pmid">35078469</pub-id><pub-id pub-id-type="pmcid">PMC8789481</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weiss</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Dishon</surname><given-names>M</given-names></name>. <article-title>On the asymptotic behavior of the stochastic and deterministic models of an epidemic</article-title>. <source>Mathematical Biosciences.</source><year>1971</year>;<volume>11</volume>(3&#8211;4):<fpage>261</fpage>&#8211;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0025-5564(71)90087-3</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hoppensteadt</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Waltman</surname><given-names>P</given-names></name>. <article-title>A problem in the theory of epidemics, II</article-title>. <source>Mathematical Biosciences.</source><year>1971</year>;<volume>12</volume>(1&#8211;2):<fpage>133</fpage>&#8211;<lpage>45</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0025-5564(71)90078-2</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lajmanovich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yorke</surname><given-names>JA</given-names></name>. <article-title>A deterministic model for gonorrhea in a nonhomogeneous population</article-title>. <source>Mathematical Biosciences.</source><year>1976</year>;<volume>28</volume>(3&#8211;4):<fpage>221</fpage>&#8211;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0025-5564(76)90125-5</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Grassly</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Garnett</surname><given-names>GP</given-names></name>. <article-title>Host immunity and synchronized epidemics of syphilis across the United States</article-title>. <source>Nature.</source><year>2005</year>;<volume>433</volume>(<issue>7024</issue>):<fpage>417</fpage>&#8211;<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature03072</pub-id><pub-id pub-id-type="pmid">15674292</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref017"><label>17</label><mixed-citation publication-type="other">Liu W, Levin SA. Influenza and some related mathematical models. Biomathematics. Berlin, Heidelberg: Springer; 1989. p. 235&#8211;52. <pub-id pub-id-type="doi">10.1007/978-3-642-61317-3_10</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Halloran</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Watelet</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Struchiner</surname><given-names>CJ</given-names></name>. <article-title>Epidemiologic effects of vaccines with complex direct effects in an age-structured population</article-title>. <source>Math Biosci.</source><year>1994</year>;<volume>121</volume>(<issue>2</issue>):<fpage>193</fpage>&#8211;<lpage>225</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0025-5564(94)90070-1</pub-id><pub-id pub-id-type="pmid">8054765</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McLean</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Blower</surname><given-names>SM</given-names></name>. <article-title>Modelling HIV vaccination</article-title>. <source>Trends in Microbiology.</source><year>1995</year>;<volume>3</volume>(<issue>12</issue>):<fpage>458</fpage>&#8211;<lpage>63</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0966-842x(00)89010-1</pub-id><pub-id pub-id-type="pmid">8800836</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref020"><label>20</label><mixed-citation publication-type="other">Park SW, Li M, Metcalf CJE, Dusho&#239;&#172;&#8364; J. Immune boosting bridges leaky and polarized vaccination models. 2023.</mixed-citation></ref><ref id="pcbi.1013399.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Smith</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Rodrigues</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Fine</surname><given-names>PE</given-names></name>. <article-title>Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies</article-title>. <source>Int J Epidemiol.</source><year>1984</year>;<volume>13</volume>(<issue>1</issue>):<fpage>87</fpage>&#8211;<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ije/13.1.87</pub-id><pub-id pub-id-type="pmid">6698708</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lind</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Dorion</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Houde</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Lansing</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lapidus</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population</article-title>. <source>Nat Commun.</source><year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>5055</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-023-40750-8</pub-id><pub-id pub-id-type="pmid">37598213</pub-id><pub-id pub-id-type="pmcid">PMC10439918</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reyn&#233;</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Richard</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Selinger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Djidjou-Demasse</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Alizon</surname><given-names>S</given-names></name>. <article-title>Non-Markovian modelling highlights the importance of age structure on Covid-19 epidemiological dynamics</article-title>. <source>Math Model Nat Phenom.</source><year>2022</year>;<volume>17</volume>:<fpage>7</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1051/mmnp/2022008</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reyn&#233;</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Djidjou-Demasse</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Alizon</surname><given-names>S</given-names></name>. <article-title>Mutant emergence timing and population immunisation status impact epidemiological dynamics</article-title>. <source>J Theor Biol.</source><year>2025</year>;<volume>608</volume>:<fpage>112140</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jtbi.2025.112140</pub-id><pub-id pub-id-type="pmid">40348170</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref025"><label>25</label><mixed-citation publication-type="other">Report SPF. 2020. <ext-link xlink:href="https://www.santepubliquefrance.fr/etudes-et-enquetes/covid-19-etudes-pour-suivre-la-part-de-la-population-infectee-par-le-sars-cov-2-en-france" ext-link-type="uri">https://www.santepubliquefrance.fr/etudes-et-enquetes/covid-19-etudes-pour-suivre-la-part-de-la-population-infectee-par-le-sars-cov-2-en-france</ext-link></mixed-citation></ref><ref id="pcbi.1013399.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Alizon</surname><given-names>S</given-names></name>. <article-title>Anticipating COVID-19 intensive care unit capacity strain: a look back at epidemiological projections in France</article-title>. <source>Anaesth Crit Care Pain Med.</source><year>2021</year>;<volume>40</volume>(<issue>4</issue>):<fpage>100943</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.accpm.2021.100943</pub-id><pub-id pub-id-type="pmid">34479681</pub-id><pub-id pub-id-type="pmcid">PMC8407772</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Crellen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Pollington</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Lucas</surname><given-names>TCD</given-names></name>, <name name-style="western"><surname>Ayabina</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Dynamics of SARS-CoV-2 with waning immunity in the UK population</article-title>. <source>Philos Trans R Soc Lond B Biol Sci.</source><year>2021</year>;<volume>376</volume>(<issue>1829</issue>):<fpage>20200274</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rstb.2020.0274</pub-id><pub-id pub-id-type="pmid">34053264</pub-id><pub-id pub-id-type="pmcid">PMC8165597</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bushman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kahn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hanage</surname><given-names>WP</given-names></name>. <article-title>Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape</article-title>. <source>Cell.</source><year>2021</year>;<volume>184</volume>(<issue>26</issue>):6229-6242.e18. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2021.11.026</pub-id><pub-id pub-id-type="pmid">34910927</pub-id><pub-id pub-id-type="pmcid">PMC8603072</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Barnard</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>NG</given-names></name>, Centre for Mathematical Modelling of Infectious Diseases COVID-19 Working Group, <name name-style="western"><surname>Jit</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Edmunds</surname><given-names>WJ</given-names></name>. <article-title>Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era</article-title>. <source>Nat Commun.</source><year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>4879</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-022-32404-y</pub-id><pub-id pub-id-type="pmid">35986002</pub-id><pub-id pub-id-type="pmcid">PMC9389516</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sonabend</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Whittles</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Imai</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Perez-Guzman</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>Knock</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Rawson</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study</article-title>. <source>Lancet.</source><year>2021</year>;<volume>398</volume>(<issue>10313</issue>):<fpage>1825</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02276-5</pub-id><pub-id pub-id-type="pmid">34717829</pub-id><pub-id pub-id-type="pmcid">PMC8550916</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gomes</surname><given-names>MGM</given-names></name>, <name name-style="western"><surname>White</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Medley</surname><given-names>GF</given-names></name>. <article-title>Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives</article-title>. <source>J Theor Biol.</source><year>2004</year>;<volume>228</volume>(<issue>4</issue>):<fpage>539</fpage>&#8211;<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jtbi.2004.02.015</pub-id><pub-id pub-id-type="pmid">15178201</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gomes</surname><given-names>MGM</given-names></name>, <name name-style="western"><surname>White</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Medley</surname><given-names>GF</given-names></name>. <article-title>The reinfection threshold</article-title>. <source>J Theor Biol.</source><year>2005</year>;<volume>236</volume>(<issue>1</issue>):<fpage>111</fpage>&#8211;<lpage>3</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jtbi.2005.03.001</pub-id><pub-id pub-id-type="pmid">15967188</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Le</surname><given-names>A</given-names></name>, <name name-style="western"><surname>King</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Magpantay</surname><given-names>FMG</given-names></name>, <name name-style="western"><surname>Mesbahi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rohani</surname><given-names>P</given-names></name>. <article-title>The impact of infection-derived immunity on disease dynamics</article-title>. <source>J Math Biol.</source><year>2021</year>;<volume>83</volume>(6&#8211;7):<fpage>61</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00285-021-01681-4</pub-id><pub-id pub-id-type="pmid">34773173</pub-id><pub-id pub-id-type="pmcid">PMC8589100</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Magpantay</surname><given-names>FMG</given-names></name>, <name name-style="western"><surname>Riolo</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>DE Cell&#232;s</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>King</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Rohani</surname><given-names>P</given-names></name>. <article-title>Epidemiological consequences of imperfect vaccines for immunizing infections</article-title>. <source>SIAM J Appl Math.</source><year>2014</year>;<volume>74</volume>(<issue>6</issue>):<fpage>1810</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1137/140956695</pub-id><pub-id pub-id-type="pmid">25878365</pub-id><pub-id pub-id-type="pmcid">PMC4394665</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hall</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Foulkes</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Charlett</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Atti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Monk</surname><given-names>EJM</given-names></name>, <name name-style="western"><surname>Simmons</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)</article-title>. <source>Lancet.</source><year>2021</year>;<volume>397</volume>(<issue>10283</issue>):<fpage>1459</fpage>&#8211;<lpage>69</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00675-9</pub-id><pub-id pub-id-type="pmid">33844963</pub-id><pub-id pub-id-type="pmcid">PMC8040523</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Servellita</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Syed</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Brazer</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Saldhi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Garcia-Knight</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants</article-title>. <source>Cell.</source><year>2022</year>;<volume>185</volume>(<issue>9</issue>):1539-1548.e5. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2022.03.019</pub-id><pub-id pub-id-type="pmid">35429436</pub-id><pub-id pub-id-type="pmcid">PMC8930394</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Callow</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Parry</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Sergeant</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tyrrell</surname><given-names>DA</given-names></name>. <article-title>The time course of the immune response to experimental coronavirus infection of man</article-title>. <source>Epidemiol Infect.</source><year>1990</year>;<volume>105</volume>(<issue>2</issue>):<fpage>435</fpage>&#8211;<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1017/s0950268800048019</pub-id><pub-id pub-id-type="pmid">2170159</pub-id><pub-id pub-id-type="pmcid">PMC2271881</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Edridge</surname><given-names>AWD</given-names></name>, <name name-style="western"><surname>Kaczorowska</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hoste</surname><given-names>ACR</given-names></name>, <name name-style="western"><surname>Bakker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Loens</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Seasonal coronavirus protective immunity is short-lasting</article-title>. <source>Nat Med.</source><year>2020</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1691</fpage>&#8211;<lpage>3</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41591-020-1083-1</pub-id><pub-id pub-id-type="pmid">32929268</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zachreson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tobin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Szanyi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cromer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shearer</surname><given-names>FM</given-names></name>, <etal>et al</etal>. <article-title>Individual variation in vaccine immune response can produce bimodal distributions of protection</article-title>. <source>Vaccine.</source><year>2023</year>;<volume>41</volume>(<issue>45</issue>):<fpage>6630</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.09.025</pub-id><pub-id pub-id-type="pmid">37793975</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Richard</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Alizon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Choisy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Djidjou-Demasse</surname><given-names>R</given-names></name>. <article-title>Age-structured non-pharmaceutical interventions for optimal control of COVID-19 epidemic</article-title>. <source>PLoS Comput Biol.</source><year>2021</year>;<volume>17</volume>(<issue>3</issue>):e1008776. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008776</pub-id><pub-id pub-id-type="pmid">33661890</pub-id><pub-id pub-id-type="pmcid">PMC7963091</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hethcote</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Stech</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Van Den Driessche</surname><given-names>P</given-names></name>. <article-title>Nonlinear oscillations in epidemic models</article-title>. <source>SIAM J Appl Math.</source><year>1981</year>;<volume>40</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1137/0140001</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>El Khalifi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Britton</surname><given-names>T</given-names></name>. <article-title>Extending susceptible-infectious-recovered-susceptible epidemics to allow for gradual waning of immunity</article-title>. <source>J R Soc Interface.</source><year>2023</year>;<volume>20</volume>(<issue>206</issue>):<fpage>20230042</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rsif.2023.0042</pub-id><pub-id pub-id-type="pmid">37700711</pub-id><pub-id pub-id-type="pmcid">PMC10498349</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Carlsson</surname><given-names>R-M</given-names></name>, <name name-style="western"><surname>Childs</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Glasser</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Heffernan</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Modeling the waning and boosting of immunity from infection or vaccination</article-title>. <source>J Theor Biol.</source><year>2020</year>;<volume>497</volume>:<fpage>110265</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jtbi.2020.110265</pub-id><pub-id pub-id-type="pmid">32272134</pub-id><pub-id pub-id-type="pmcid">PMC9108945</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Calvetti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Somersalo</surname><given-names>E</given-names></name>. <article-title>Post-pandemic modeling of COVID-19: waning immunity determines recurrence frequency</article-title>. <source>Math Biosci.</source><year>2023</year>;<volume>365</volume>:<fpage>109067</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.mbs.2023.109067</pub-id><pub-id pub-id-type="pmid">37708989</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hurtado</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Kirosingh</surname><given-names>AS</given-names></name>. <article-title>Generalizations of the &#8220;Linear Chain Trick&#8221;: incorporating more flexible dwell time distributions into mean field ODE models</article-title>. <source>J Math Biol.</source><year>2019</year>;<volume>79</volume>(<issue>5</issue>):<fpage>1831</fpage>&#8211;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00285-019-01412-w</pub-id><pub-id pub-id-type="pmid">31410551</pub-id><pub-id pub-id-type="pmcid">PMC6800873</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Halloran</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Struchiner</surname><given-names>CJ</given-names></name>. <article-title>Thirty-five years of leaky vaccines</article-title>. <source>Am J Epidemiol.</source><year>2025</year>;<volume>194</volume>(<issue>4</issue>):<fpage>918</fpage>&#8211;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/aje/kwae379</pub-id><pub-id pub-id-type="pmid">39359003</pub-id><pub-id pub-id-type="pmcid">PMC11978606</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref047"><label>47</label><mixed-citation publication-type="other">Cell&#232;s MD, Wong A, Dalby T, Rohani P. Immune boosting and the perils of interpreting pertussis seroprevalence studies. 2025. <ext-link xlink:href="https://www.medrxiv.org/content/10.1101/2025.03.18.25324179v1" ext-link-type="uri">https://www.medrxiv.org/content/10.1101/2025.03.18.25324179v1</ext-link></mixed-citation></ref><ref id="pcbi.1013399.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Graham</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Regoes</surname><given-names>RR</given-names></name>. <article-title>Dose-dependent interaction of parasites with tiers of host defense predicts &#8220;wormholes&#8221; that prolong infection at intermediate inoculum sizes</article-title>. <source>PLoS Comput Biol.</source><year>2024</year>;<volume>20</volume>(<issue>12</issue>):e1012652. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1012652</pub-id><pub-id pub-id-type="pmid">39642189</pub-id><pub-id pub-id-type="pmcid">PMC11654943</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Roquebert</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Foulongne</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Morquin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Verdurme</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Trombert-Paolantoni</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Analyzing, modeling the spread of SARS-CoV-2 omicron lineages BA.1, BA.2, France and September 2021 -February 2022</article-title>. <source>Emerg Infect Dis.</source><year>2022</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1355</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3201/eid2807.220033</pub-id><pub-id pub-id-type="pmid">35642476</pub-id><pub-id pub-id-type="pmcid">PMC9239895</pub-id></mixed-citation></ref><ref id="pcbi.1013399.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kamiya</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Alvarez-Iglesias</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sofonea</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Fitz-Simon</surname><given-names>N</given-names></name>. <article-title>Estimating time-dependent contact: a multi-strain epidemiological model of SARS-CoV-2 on the island of Ireland</article-title>. <source>Glob Epidemiol.</source><year>2023</year>;<volume>5</volume>:<fpage>100111</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.gloepi.2023.100111</pub-id><pub-id pub-id-type="pmid">37162815</pub-id><pub-id pub-id-type="pmcid">PMC10159265</pub-id></mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="pcbi.1013399.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Leitner</surname><given-names initials="T">Thomas</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kusejko</surname><given-names initials="K">Katharina</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Leitner, Kusejko</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Leitner, Kusejko</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1013399" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">23 Feb 2025</named-content>
</p><p>&#160;PCOMPBIOL-D-25-00077</p><p>Leaky or polarised immunity: non-Markovian modelling highlights the impact of immune memory assumptions</p><p>PLOS Computational Biology</p><p>Dear Dr. Reyn&#233;,</p><p>Thank you for submitting your manuscript to PLOS Computational Biology. After careful consideration, we feel that it has merit but does not fully meet PLOS Computational Biology's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>All three reviewers appreciated the importance of the topic, however raised some concerns regarding technical choices and interpretation of the results. Further, the reviewers highlighted that various crucial aspects are somewhat hidden in the appendix, hence strongly suggest to restructure the manuscript in order to improve the reading flow and present all main aspects in the main body of the paper. In addition, various clarifications and language improvements are needed. Please find below the three detailed reviewer reports.</p><p>&#8203;Please submit your revised manuscript within 60 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>ploscompbiol@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pcompbiol/" ext-link-type="uri">https://www.editorialmanager.com/pcompbiol/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p>* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to formatting updates and technical items listed in the 'Journal Requirements' section below.</p><p>* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p><p>* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p><p>If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Katharina Kusejko</p><p>Academic Editor</p><p>PLOS Computational Biology</p><p>Thomas Leitner</p><p>Section Editor</p><p>PLOS Computational Biology</p><p>
<bold>Journal Requirements:</bold>
</p><p>1) We ask that a manuscript source file is provided at Revision. Please upload your manuscript file as a .doc, .docx, .rtf or .tex. If you are providing a .tex file, please upload it under the item type u2018LaTeX Source Fileu2019 and leave your .pdf version as the item type u2018Manuscriptu2019.</p><p>2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:&#160;</p><p>
<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/figures" ext-link-type="uri">https://journals.plos.org/ploscompbiol/s/figures</ext-link>
</p><p>3) We notice that your supplementary Figures, and information are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.</p><p>4) Some material included in your submission may be copyrighted. According to PLOSu2019s copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOSu2019s copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use PLOS's Copyright Content Permission form.</p><p>Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager.&#160;</p><p>Potential Copyright Issues:</p><p>i) Figures 1A, and 1B. Please confirm whether you drew the images / clip-art within the figure panels by hand. If you did not draw the images, please provide (a) a link to the source of the images or icons and their license / terms of use; or (b) written permission from the copyright holder to publish the images or icons under our CC BY 4.0 license. Alternatively, you may replace the images with open source alternatives. See these open source resources you may use to replace images / clip-art:</p><p>- <ext-link xlink:href="https://commons.wikimedia.org" ext-link-type="uri">https://commons.wikimedia.org</ext-link></p><p>- <ext-link xlink:href="https://openclipart.org/" ext-link-type="uri">https://openclipart.org/</ext-link>.</p><p>
<bold>Reviewers' comments:</bold>
</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Authors:</bold>
</p><p>
<bold>Please note that two reviews are&#160;uploaded as&#160;attachments.</bold>
</p><p>Reviewer #1:&#160;The manuscript investigates an important and interesting question in infectious disease modeling: How does the specific formalism used to describe immunity waning influence model dynamics/outcomes. The authors compare the leaky formalism (recovered individuals become more and more susceptible to reinfection as time since last infection/vaccination increases) and the polarized formalism (recovered individuals are fully immune but become fully susceptible over time). These two formalisms are frequently used in infectious disease models. For COVID-19 and many other diseases, the former formalism appears to be more useful but polarized immunity cannot be completely discounted. The authors display a great understanding of mathematical epidemiology and nicely motivate the choice of modeling framework. That being said, the most interesting discussions and answers related to the research question are in the various appendices (I am not sure why). The large number of appendices negatively affects the flow of the paper. Moreover, this manuscript suffers from poor English. While I realize that the authors are French and likely lack a native English speaker, a lot of the typos and grammar issues could have been prevented by the use of same English language software, e.g. Microsoft Word. Further, wording is at times confusing and the brevity of many explanations (i.e., lack of details) makes it hard to follow along.</p><p>Most importantly, I have severe concerns about the research findings. 1. The claim &#8220;the time between reinfections is always shorter with a leaky formalism&#8221; appears to be obvious given the way the authors implemented the two formalisms, specifically given the assumption of constant force of infection and in the absence of disease dynamics. See major comment 1 below. 2. The COVID-19 results appear to be largely confounded by assumptions made about initial conditions, which are not described anywhere, so I can only assume that the authors assumed everyone was recently recovered with 0 days since last immunity event at the onset of the Omicron waves, clearly a wrong assumption that affects the comparison between the leaky and polarized formalism. See major comment 2 below.</p><p>Major comments:</p><p>1. The authors should provide more details in the results section, clarifying the assumptions underlying the finding &#8220;the time between reinfections is always shorter with a leaky formalism&#8221;, specifically focusing on the validity of the strong assumption of a constant force of infection. Upon reading the Methods in detail I came to the conclusion that the results shown in Fig S1 in support of the claim &#8220;the time between reinfections is always shorter with a leaky formalism&#8221; are in a way a &#8220;self-fulfilling prophecy/circular conclusion&#8221;: The authors use the exact same function f in both formalisms. The polarized formalism assumes individuals that &#8220;lose immunity&#8221; become first susceptible, at which point they are susceptible to infection. The leaky formalism assumes individuals are always vulnerable to infection but a decreased rate. In other words, individuals are moved into the S and I compartment at the same rate, parametrized by the function f, in the polarized and leaky formalism, respectively. Naturally, this means reinfections occur earlier in the leaky formalism. We don&#8217;t need a model to obtain this result, as long as the force of infection is assumed to be constant and the same for the two formalisms. Note: the authors are aware of this, and derive this result, somewhat confusingly and with many assumptions, in Appendix E.</p><p>2. Figure 2 is very nice and helpful. It would be nice if the authors could add further details to the main text (Lines 91-94), specifically related to the initial values used in the models: at the beginning of the omicron wave (when the authors assume everyone has attained some immunity through infection or vaccination), how is the population distributed in terms of age of immunity in R^D_{t=0,a}, and what proportion, in the polarized formalism, starts in S^D? This strongly affects the outcomes! I could not find any information regarding this. Side note: Not everyone will have been infected with Delta. I would change &#8220;Last infection by Delta VOC&#8221; to something like &#8220;Immunity due to non-Omicron infection or vaccination&#8221;. See and modify also lines 220-225.</p><p>3. The 95% posterior trajectories intervals look identical for the leaky and the polarized formalism. Are the authors sure that this is correct and not a copy paste error? Given differences in the number of reinfections between the formalisms, I would expect to see differences in hospital admissions as well. Also, the total number of reinfections appears to be almost double in the leaky vs all-or-nothing formalism (3B) but the differences in daily infections (3C) are much smaller. This is strange, or am I missing something? Lastly, the authors should explain in the Results what exactly the &#8220;probability of hospitalization&#8221; refers to.</p><p>4. The appendix should not include new results. All results and supplementary figures should be referred to in the main manuscript, e.g., the global sensitivity analyses.</p><p>Minor comments:</p><p>L17: It would be nice if the authors could expand a little on &#8220;conservative assumptions&#8221;, either rewrite or add some more info.</p><p>L44/45: The sentence for the leaky vaccine is wrong. The decrease in susceptible is of size x, not 1-x. I.e., if x=80%, then the susceptibility of vaccinated/recovered individuals is 1-x = 20% compared to that of non-vaccinated/non-recovered people.</p><p>Fig 1C: R_N in black on dark blue cannot be read.</p><p>L86: awkward wording: &#8220;hardly remains generalisable&#8221; - is it generalizable or not? are the multiple reinfections the issue or the dynamical (i.e., non-constant force of infection) setting?</p><p>L155: a bimodal distribution of immune efficacy. It is unclear how this ties in with using antibody levels as correlates of protection. I hope the authors can clarify this in the text by rewriting/expanding this paragraph.</p><p>L504-514: I do not get the purpose of this paragraph. Using the strict definition of non-Markovian, yes, an SEIR model can be seen as non-Markovian. However, the way an SEIR model is typically implemented (using a fixed transition rate from E to I) it is indeed Markovian. The authors should clarify their point. Especially, because according to lines 528-530, the standard SEIR model would be Markovian even according to the authors.</p><p>616 &#8220;proportion of individualS that HAVE become &#8230;&#8221; - it&#8217;s important to</p><p>Appendix G: It would be nice to see plots/statistics that exhibit the goodness of fit between the hypo-exponential and Gamma distributions.</p><p>Sobol&#8217;s indices should be followed by a reference. Also, the information provided related to the sensitivity analysis is insufficient to reproduce the results.</p><p>Language:</p><p>L4: "and" not "or"</p><p>L14/15: "made the ...", grammar</p><p>L25: p missing: susceptible</p><p>L26/27: &#8220;It is the case of the first studies&#8221; - strange wording, not sure what exactly this means.</p><p>L45/46: if x in [0,1], get rid of % signs everywhere here. Or let x in [0,100] but that is the worse choice.</p><p>L47: delete to in &#8220;or to natural&#8221;</p><p>Fig 1 caption: simplest, not most simple</p><p>L64: assesS</p><p>L63: strange wording &#8220;This is partic- ularly the case of the study by&#8221;</p><p>L65: strange wording &#8220;as it should be studied further&#8221;</p><p>l74: &#8220;using simple modelS&#8221; or &#8220;using A simple model&#8221;</p><p>L128: &#8220;can fo unnoticed&#8221;???</p><p>L147: strange wording: &#8220;never discontinued to assess &#8220;</p><p>l170: strange use of &#8220;verifies&#8221;: we introduce the following function that verifies for all a</p><p>Fig 2 caption: the only difference &#8230; IS the following:</p><p>L212: witH</p><p>L215: not sure what this is supposed to mean: &#8220;We implement the two types of immunity described to SARS-CoV-2 incidence data&#8220;</p><p>L222: to illustrate, not illustrated</p><p>L433: grammar: &#8220;in every cases&#8221;</p><p>l433: I would add the word partial: &#8220;we assume partial immunity to last&#8230; &#8220;</p><p>L438: strange wording: &#8220;which is an order of magnitude observed quite frequently &#8220;</p><p>L480: replace &#8220;will&#8221; by &#8220;ability&#8221;?</p><p>L482: strange wording: &#8220;It will manifest itself through a wide variety of approaches over time&#8221;. E.g., why is future tense used?</p><p>l489: replace &#8220;may allow using of&#8221; by &#8220;enables the use of the&#8221;</p><p>L552: &#8220;implying a manual Euler scheme&#8221; is confusing. How about (if this is what the authors mean): &#8220;requiring the implementation of a manual Euler scheme&#8221;</p><p>l552: replace &#8220;way more easy&#8221; by &#8220;easier&#8221;</p><p>L558: awkward: &#8220;the choice goes to the modeller who will choose&#8221;</p><p>L566: become, no s</p><p>L570: &#8220;become infected becomeS&#8221;</p><p>577: &#8220;SAME&#8221; not smae</p><p>581: noticeD</p><p>585: would may ??</p><p>586: &#8220;The used Equation&#8221; - which equation? Why capitalize equation?</p><p>587: grammar: &#8220;as it do no involve&#8221;</p><p>607: re-infected, other places: reinfected - be consistent</p><p>609: I would add: &#8220;fully recovered (I.E., FULLY IMMUNE) before being &#8230;&#8221;</p><p>623: strange wording: &#8220;move also on the age of immunity support as time flies&#8221;</p><p>642: t_2</p><p>654: delete &#8220;we made&#8221;</p><p>655: Model equations</p><p>677: from of</p><p>This list is by no means exclusive. Any English language program, e.g. Microsoft Word, would have caught &gt;50% of these errors.</p><p>Reviewer #2:&#160;Kindly refer to the attached report for details.</p><p>Reviewer #3:&#160;The review is uploaded as an attachment.</p><p>**********</p><p>
<bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
</p><p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code &#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;None</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #1:&#160;No</p><p>Reviewer #2:&#160;No</p><p>Reviewer #3:&#160;No</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>
<bold>Figure resubmission:</bold>
</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step. If there are other&#160;versions of&#160;figure files still present in your&#160;submission file inventory at resubmission, please replace them with the PACE-processed versions.</p><p>
<bold>Reproducibility:</bold>
</p><p>To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p><supplementary-material id="pcbi.1013399.s002" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PCOMPBIOL-D-25-00077(Review Report).docx</named-content></p></caption><media xlink:href="pcbi.1013399.s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pcbi.1013399.s003" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Review Leaky vs Polarised.pdf</named-content></p></caption><media xlink:href="pcbi.1013399.s003.pdf" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pcbi.1013399.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r002</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article related-article-type="editor-report" id="rel-obj002" xml:lang="en" journal-id="PLoS Comput Biol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40828879"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">28 Apr 2025</named-content>
</p><supplementary-material id="pcbi.1013399.s004" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">REBUTTAL.pdf</named-content></p></caption><media xlink:href="pcbi.1013399.s004.pdf" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pcbi.1013399.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Leitner</surname><given-names initials="T">Thomas</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kusejko</surname><given-names initials="K">Katharina</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Leitner, Kusejko</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Leitner, Kusejko</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article related-article-type="reviewed-article" id="rel-obj003" xml:lang="en" journal-id="PLoS Comput Biol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40828879"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">4 Jun 2025</named-content>
</p><p>PCOMPBIOL-D-25-00077R1</p><p>Leaky or polarised immunity: non-Markovian modelling highlights the impact of immune memory assumptions</p><p>PLOS Computational Biology</p><p>Dear Dr. Reyn&#233;,</p><p>Thank you for submitting your manuscript to PLOS Computational Biology. After careful consideration, we feel that it has merit but does not fully meet PLOS Computational Biology's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript within 30 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>ploscompbiol@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pcompbiol/" ext-link-type="uri">https://www.editorialmanager.com/pcompbiol/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p>* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to formatting updates and technical items listed in the 'Journal Requirements' section below.</p><p>* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p><p>* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p><p>If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Katharina Kusejko</p><p>Academic Editor</p><p>PLOS Computational Biology</p><p>Thomas Leitner</p><p>Section Editor</p><p>PLOS Computational Biology</p><p>
<bold>Journal Requirements:</bold>
</p><p>1) Please provide a completed 'Competing Interests' statement, including any COIs declared by your co-authors. If you have no competing interests to declare, please state "The authors have declared that no competing interests exist".</p><p>2) Please include the authors' affiliations in the online submission form. Please ensure that the affiliations of the authors listed on the manuscript title page do exactly match with the affiliations provided in the online submission form</p><p>NOTE: Affiliations should include a department (if applicable), an institution, a city, and a country.</p><p>
<bold>Reviewers' comments:</bold>
</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Authors:</bold>
</p><p>
<bold>Please note that two reviews are&#160;uploaded as attachments.</bold>
</p><p>Reviewer #1:&#160;The authors took the comments and concerns from me and other reviewers seriously and the revised manuscript is substantially improved. I just have a few language suggestions.</p><p>Language:</p><p>l113: delete "epsilon(tau) where"</p><p>l162: replace "divergences" by "differences"</p><p>l192: "a unique" not "an unique"</p><p>Note: all my line number references are based on the marked up manuscript page numbers.</p><p>Reviewer #2:&#160;Please refer to the attached file.</p><p>Reviewer #3:&#160;The review is uploaded as an attachment.</p><p>**********</p><p>
<bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
</p><p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code &#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold>Claus Kadelka</p><p>Reviewer #2:&#160;No</p><p>Reviewer #3:&#160;<bold>Yes:&#160;</bold>Anna Bot</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>
<bold>Figure resubmission:</bold>
</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions.</p><p>
<bold>Reproducibility:</bold>
</p><p>To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p><supplementary-material id="pcbi.1013399.s005" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PCOMPBIOL-D-25-00077(Review Report) (2).docx</named-content></p></caption><media xlink:href="pcbi.1013399.s005.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pcbi.1013399.s006" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Review_PLOS_2_R1.pdf</named-content></p></caption><media xlink:href="pcbi.1013399.s006.pdf" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pcbi.1013399.r004"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r004</article-id><title-group><article-title>Author response to Decision Letter 2</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1013399" id="rel-obj004" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">12 Jun 2025</named-content>
</p><supplementary-material id="pcbi.1013399.s007" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">REBUTAL_R2.pdf</named-content></p></caption><media xlink:href="pcbi.1013399.s007.pdf" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pcbi.1013399.r005" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r005</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Leitner</surname><given-names initials="T">Thomas</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kusejko</surname><given-names initials="K">Katharina</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Leitner, Kusejko</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Leitner, Kusejko</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1013399" id="rel-obj005" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">9 Jul 2025</named-content>
</p><p>PCOMPBIOL-D-25-00077R2</p><p>Leaky or polarised immunity: non-Markovian modelling highlights the impact of immune memory assumptions</p><p>PLOS Computational Biology</p><p>Dear Dr. Reyn&#233;,</p><p>Thank you for submitting your manuscript to PLOS Computational Biology. We received additional comments on the revised version of your manuscript, mostly concerning clarifying parameter choices and some inconsistencies with the notations, as well as some smaller adjustments. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised.</p><p>Please submit your revised manuscript within 30 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>ploscompbiol@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pcompbiol/" ext-link-type="uri">https://www.editorialmanager.com/pcompbiol/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p>* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to formatting updates and technical items listed in the 'Journal Requirements' section below.</p><p>* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p><p>* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p><p>If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Katharina Kusejko</p><p>Academic Editor</p><p>PLOS Computational Biology</p><p>Thomas Leitner</p><p>Section Editor</p><p>PLOS Computational Biology</p><p>
<bold>Reviewers' comments:</bold>
</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Authors:</bold>
</p><p>
<bold>Please note&#160;that the review is uploaded as an attachment.</bold>
</p><p>Reviewer #2:&#160;Please refer to the attached document</p><p>**********</p><p>
<bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
</p><p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code &#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #2:&#160;None</p><p>**********</p><p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #2:&#160;No</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>
<bold>Figure resubmission:</bold>
</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions.</p><p>
<bold>Reproducibility:</bold>
</p><p>To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p><supplementary-material id="pcbi.1013399.s008" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">PCOMPBIOL-D-25-00077_R2(JUN30).pdf</named-content></p></caption><media xlink:href="pcbi.1013399.s008.pdf" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pcbi.1013399.r006"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r006</article-id><title-group><article-title>Author response to Decision Letter 3</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1013399" id="rel-obj006" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>3</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">29 Jul 2025</named-content>
</p><supplementary-material id="pcbi.1013399.s009" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">RESPONSE_R3.pdf</named-content></p></caption><media xlink:href="pcbi.1013399.s009.pdf" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="editor-report" id="pcbi.1013399.r007" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r007</article-id><title-group><article-title>Decision Letter 3</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Leitner</surname><given-names initials="T">Thomas</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kusejko</surname><given-names initials="K">Katharina</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Leitner, Kusejko</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Leitner, Kusejko</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1013399" id="rel-obj007" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>3</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">6 Aug 2025</named-content>
</p><p>Dear Dr. Reyn&#233;,</p><p>We are pleased to inform you that your manuscript 'Leaky or polarised immunity: non-Markovian modelling highlights the impact of immune memory assumptions' has been provisionally accepted for publication in PLOS Computational Biology.</p><p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.</p><p>Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.</p><p>IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.</p><p>Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.</p><p>Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology.&#160;</p><p>Best regards,</p><p>Katharina Kusejko</p><p>Academic Editor</p><p>PLOS Computational Biology</p><p>Thomas Leitner</p><p>Section Editor</p><p>PLOS Computational Biology</p><p>***********************************************************</p></body></sub-article><sub-article article-type="editor-report" id="pcbi.1013399.r008" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pcbi.1013399.r008</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Leitner</surname><given-names initials="T">Thomas</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kusejko</surname><given-names initials="K">Katharina</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Leitner, Kusejko</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Leitner, Kusejko</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1013399" id="rel-obj008" related-article-type="reviewed-article"/></front-stub><body><p>PCOMPBIOL-D-25-00077R3</p><p>Leaky or polarised immunity: non-Markovian modelling highlights the impact of immune memory assumptions</p><p>Dear Dr Reyn&#233;,</p><p>I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.</p><p>The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.</p><p>Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p><p>You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at <ext-link xlink:href="https://explore.plos.org/phishing" ext-link-type="uri">https://explore.plos.org/phishing</ext-link>.</p><p>Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!</p><p>With kind regards,</p><p>Zsofia Freund</p><p>PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom <email>ploscompbiol@plos.org</email> | Phone +44 (0) 1223-442824 | ploscompbiol.org | @PLOSCompBiol</p></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>